Arcellx, INC

Arcellx, Inc. has been acquired by Gilead Sciences, Inc. for approximately $7.1 billion, marking the completion of a tender offer and subsequent merger.

Gilead Sciences will acquire Arcellx for an implied equity value of $7.8 billion, including a $115 cash per share and a $5 contingent value right, to gain full control of the promising anito-cel CAR T-cell therapy for multiple myeloma.

Arcellx announced new positive data from its pivotal Phase 2 iMMagine-1 study for anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma, demonstrating high response rates and a manageable safety profile.

Arcellx, Inc. announced its third quarter 2025 financial results, reporting a significant decrease in collaboration revenue and an increased net loss compared to the prior year.

Arcellx announced positive Phase 2 iMMagine-1 study data for anito-cel in RRMM, FDA clearance for ACLX-004 IND, and Q2 2025 financial results with cash runway into 2028.

Arcellx, Inc. announced the successful outcomes of its Annual Meeting of Stockholders held on May 28, 2025, with all proposed matters, including director elections, executive compensation, and auditor ratification, receiving strong shareholder approval.

Arcellx reported significantly increased net losses for Q3 and 9M 2025, driven by higher operating expenses and reduced collaboration revenue, while maintaining a cash runway into 2028.

Arcellx reports increased net losses in Q2 2025 despite a strong cash position, as collaboration revenue declines and R&D expenses rise for its cell therapy pipeline.

Arcellx's Q1 2025 shows a decrease in collaboration revenue and a significant increase in research and development expenses, leading to a larger net loss compared to Q1 2024.

Arcellx reports a net loss of $60.3 million for the nine months ended September 30, 2024, while highlighting progress in clinical trials and collaborations.

Arcellx, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting progress in its cell therapy programs and collaboration with Kite Pharma.

Arcellx's first quarter 2024 results show a significant increase in collaboration revenue, driven by its partnership with Kite Pharma, while the company continues to advance its clinical programs.

Arcellx, Inc. filed an amendment to its 2025 Annual Report to provide required Part III disclosures regarding corporate governance, executive compensation, and director information.

Arcellx announced its acquisition by Gilead Sciences for $115.00 per share plus a $5.00 CVR, following FDA acceptance of its BLA for anito-cel in relapsed or refractory multiple myeloma.

Arcellx's 10-K filing highlights positive clinical trial results for anito-cel and outlines strategic initiatives for growth in cell therapy.

Arcellx's 10-K filing details its financial status, clinical program advancements, and strategic direction in the cell therapy space.

Director Jill Carroll reports the disposition of Arcellx, Inc. shares and options following the company's acquisition by Gilead Sciences.

Arcellx, Inc. reports completion of its merger with Gilead Sciences, Inc., detailing executive stock option conversions and beneficial ownership changes.

Director Olivia C. Ware of Arcellx, Inc. has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Arcellx, Inc. Director Kavita Patel has reported transactions related to stock options following the company's merger with Gilead Sciences, Inc.

Arcellx, Inc. Director Kristin Myers has reported transactions related to the company's merger with Gilead Sciences, Inc., detailing the conversion of stock options.

Arcellx, Inc. Director David Lubner has reported changes in beneficial ownership of company stock and stock options following a merger with Gilead Sciences, Inc.

Arcellx, Inc. will hold its annual stockholders meeting virtually on May 28, 2025, to elect directors, approve executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as its independent accounting firm.

Arcellx, Inc. is holding its annual meeting of stockholders on May 28, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.

Arcellx, Inc. will hold its annual meeting of stockholders on May 24, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent auditor.

Arcellx, Inc. will hold its annual meeting of stockholders virtually on May 24, 2024, to vote on director elections, executive compensation, and auditor ratification.

New Enterprise Associates has ceased to be a beneficial owner of Arcellx, Inc. following the completion of the company's acquisition by Gilead Sciences.

Arcellx, Inc. has been acquired by Gilead Sciences, Inc. through a tender offer and subsequent merger, with shareholders receiving $115 per share plus a contingent value right.

Gilead Sciences has finalized its acquisition of Arcellx, Inc. following a successful tender offer and subsequent merger, making Arcellx a wholly owned subsidiary.

New Enterprise Associates and other major stockholders agree to tender shares in Arcellx's acquisition by Gilead Sciences for $115 cash and a $5 CVR per share.

Arcellx, Inc. shareholders to receive $115 cash plus a $5 CVR per share in Gilead Sciences acquisition.

Gilead Sciences, Inc. announced a definitive agreement to acquire Arcellx, Inc. for approximately $7.8 billion in cash and contingent value rights.

Vestal Point Capital and Ryan Wilder have filed an amendment to their Schedule 13G, reporting a 0% beneficial ownership stake in Arcellx, Inc.

The Vanguard Group has reported a 0% beneficial ownership in Arcellx Inc. common stock following an internal organizational realignment.

T. Rowe Price Investment Management, Inc. has reported a reduction in its beneficial ownership of Arcellx Inc. common stock to 4.5%.

FMR LLC and Abigail P. Johnson have filed an Amendment No. 7 to Schedule 13G, reporting a 0.5% beneficial ownership in ARCELLX INC's common stock as of February 27, 2026.

FMR LLC and Abigail P. Johnson have filed an amendment to disclose a 6.2% beneficial ownership stake in ARCELLX INC as of December 31, 2025.

T. Rowe Price Investment Management, Inc. has increased its beneficial ownership in Arcellx Inc. to 16.6% of common stock.